Aimee S Payne, MD, PhD
On the web
Overview
Dr. Payne is the Herbert and Florence Irving Professor and Chair of Dermatology at Columbia University Irving Medical Center. She received her BS degree in Biology from Stanford University and an MD/PhD degree in Molecular and Cellular Biology from Washington University School of Medicine, followed by dermatology residency and postdoctoral fellowship training at the University of Pennsylvania.
Dr. Payne is the 2024-2025 President of the Society for Investigative Dermatology and is a member of the American Society for Clinical Investigation, NIH/NIAMS Advisory Council, and International Pemphigus and Pemphigoid Foundation Medical Advisory Council. She also serves as co-chair of the Scientific Advisory Board at Cabaletta Bio, a company she co-founded to enable the first precision cellular immunotherapies for autoimmunity to enter human clinical trials.
Areas of Expertise / Conditions Treated
- Autoimmune Disease
- Blistering Disorders
- Medical Dermatology
Academic Appointments
- Herbert and Florence Irving Professor of Dermatology
Administrative Titles
- Chair, Department of Dermatology
- Dermatologist-in-Chief, NewYork-Presbyterian Hospital
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Gender
- Female
Schedule an Appointment
Virtual Visits/Telehealth
Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Phone Appointments
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Insurance Accepted
Amerigroup of New Jersey
- New Jersey Services (Medicaid Managed Care)
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
Fidelis Care
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Medicaid Managed Care
Local 1199
- Local 1199
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
Quality Health Management
- Quality Health Management
UnitedHealthcare
- Compass (Exchange)
- Empire Plan
- HMO
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
World Trade Center Health Plan
- World Trade Center Health Plan
Credentials & Experience
Education & Training
- BS, 1993 Biology, Stanford University
- MD, 2001 Washington University School of Medicine
- PhD, 2001 Molecular And Cellular Biology, Washington University School Of Medicine
- Internship: 2002 Pennsylvania Hospital
- Residency: 2005 Hospital of the University of Pennsylvania
- Fellowship: 2006 University of Pennsylvania
Committees, Societies, Councils
- 2023-2025: President of the Society for Investigative Dermatology
- Served as Chair of the National Institute of Arthritis and Musculoskeletal and Skin Diseases Board of Scientific Counselors
- Elected Member of the American Society for Clinical Investigation
- Elected Member of the American Dermatological Association
- Serves on the Medical Advisory Council of the International Pemphigus and Pemphigoid Foundation
Board Certifications
- Dermatology
Honors & Awards
- Co-Founder and Co-Chair of the Scientific Advisory Board of Cabaletta Bio
- Eugene J. Van Scott Award for Innovative Therapy, AAD
- Top 10 Clinical Research Forum Award
- American Society for Clinical Investigation
Research
Researching the pathophysiology and targeted therapy of autoantibody-mediated diseases
Dr. Payne’s clinical and research expertise centers on the diagnosis and treatment of autoimmunity, with particular focus on the autoimmune blistering diseases pemphigus and pemphigoid. Her research laboratory invented a targeted immunotherapy approach for autoimmune B cell depletion known as chimeric autoantibody receptor (CAAR) T cell therapy and performed key studies leading to FDA clearance of two Investigational New Drug Applications of CAAR T cell technology for the treatment of antigen-specific subtypes of pemphigus vulgaris and myasthenia gravis.
Research Interests
- Autoimmunity
- B cells
- CAR T Cell Therapy
- Cell adhesion
- Immune repertoire profiling
Selected Publications
- Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O’Connor KC, Herzberg U, Binder GK, Milone MC, Basu S, Payne AS: Precision targeting of autoantigen-specific B-cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T-cells. Nature Biotechnol in press, 2023.
- Tovanabutra N, Bax CE, Feng R, Kushner CJ, Payne AS: Temporal outcomes after rituximab therapy for pemphigus. J. Invest. Dermatol. 142(4): 1058-1064, 2022 Notes: doi:10.1016/j.jid.2021.09.013.
- Lee J, Lundgren DK, Mao X, Manfredo-Vieira S, Nunez-Cruz S, Williams EF, Assenmacher CA, Radaelli E, Oh S, Wang B, Ellebrecht CT, Fraietta JA, Milone MC, Payne AS: Antigen specific B-cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Invest 130(12): 6317-6324, 2020 Notes: doi:10.1172/JCI13841.
- Maehara T, Kaneko N, Perugino CA, Mattoo H, Kers J, Allard-Chamard H, Mahajan VS, Liu H, Murphy SJ, Ghebremichael M, Fox DA, Payne AS, Lafyatis R, Stone JH, Khanna D, Pillai S: Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest 130(5): 2451-2464, Jan 2020 Notes: https://doi.org/10.1172/JCI131700.
- Kushner CJ, Wang S, Tovanabutra N, Tsai DE, Werth VP, Payne AS: Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol 155(12): 1404-09, 2019 Notes: doi:10.1001/jamadermatol.2019.3236.
- Cho A, Caldara AL, Ran NA, Menne Z, Kauffman RC, Affer M, Llovet A, Norwood C, Scanlan A, Mantus G, Bradley B, Zimmer S, Schmidt T, Hertl M, Payne AS, Feldman R, Kowalczyk AP, Wrammert J : Single-cell analysis suggests that ongoing affinity maturation drives the emergence of pemphigus vulgaris autoimmune disease. Cell Rep 28(4): 909-922, Jul 23 2019.
- Ellebrecht CT, Mukherjee EM, Zheng Q, Choi EJ, Reddy SG, Mao X, Payne AS: Autoreactive IgG and IgA B cells evolve through distinct subclass switch pathways in the autoimmune disease pemphigus vulgaris. Cell Rep 24(9): 2370-2380, Aug 28 2018.
- Mao X, Cho MJ, Ellebrecht CT, Mukherjee EM, Payne AS: Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes. JCI Insight 2(9): e92253, May 4 2017.
- Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS: Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353(6295): 179-184, Jul 8 2016.
- Cho MJ, Lo ASY, Mao X, Nagler AR, Ellebrecht CT, Mukherjee EM, Hammers CM, Choi EJ, Sharma PM, Uduman M, Li H, Rux AH, Farber SA, Rubin CB, Kleinstein SH, Sachais BS, Posner MR, Cavacini LA, Payne AS: Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients. Nature Commun 5: 4167, Jun 19 2014.
For a complete list of publications, please visit PubMed.gov